Navigation Links
Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
Date:5/12/2010

XIANYANG, China, May 12 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (Nasdaq: BSPM) ("Biostar" or "the Company"), a Xianyang- based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules ("Xin Aoxing"), and a variety of pharmaceutical products, today announced that management will hold a conference call to discuss its 2010 first quarter performance at 9:30 a.m. ET on Monday, May 17, 2010. Financial results will be released on May 14, 2010 after the market closes.

Interested parties may access the call by dialing +1-877-941-4775 from within the United States, or +1-480-629-9763 if calling internationally. The conference ID is 4302147. It is advisable to dial in approximately 5-10 minutes prior to the start of the call.

A playback will be available through May 25, 2010. To listen, please call 800-406-7325 within the United States or +1 303-590-3030 when calling internationally. Utilize the pass code 4302147 for the replay.

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at http://www.viavid.net or at the following link: http://viavid.net/dce.aspx?sid=00007582 . To access the web cast, you will need to have the Windows Media Player on your desktop. For the free download of the Media Player please visit: http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary in China, develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products and two prescription-based pharmaceuticals. The Company has adopted international standards, holds one patent and is in the process of applying for two patents.

Safe Harbor

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2009, and other recent filings. These filings are available at http://www.sec.gov . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

    For further information, please contact:

     Ms. Elaine Zhao, CFO
     Tel:   +1-626-456-2789
     Email: elainezhao@biostarpharmaceuticals.com

     John Mattio
     HC International, Inc.
     Tel:   US +1-914-669-5340
     Email: john.mattio@hcinternational.net
     Web:   http://www.hcinternational.net


'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
2. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
4. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
5. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
6. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
7. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
8. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
9. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
10. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
11. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , Feb. 27, 2017  A landmark ... Vallely , MBBS, PhD, FRACS, of  Sydney Heart ... of Sydney will be published in the February ... the American College of Cardiology . According ... heart bypass surgery technique (anOPCABG) reduced postoperative ...
(Date:2/27/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully ... tests and pathology services, announced today the acceptance of ... United States and Canadian Academy of ... San Antonio, Texas . ... the Company,s extensive experience in molecular thyroid testing, including ...
(Date:2/27/2017)... AUSTIN, Texas , Feb. 27, 2017  International Biophysics ... Austin, Texas , today announced a 34% revenue growth ... a 53% increase in unit sales.  This growth was fueled ... in addition to the expansion of its global ... Shockley, Jr., International Biophysics, CEO, "As we enter our 25 ...
Breaking Medicine Technology:
(Date:2/26/2017)... Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to announce ... Mateo. Many Bay Area consumers look for home care close to home, and by ...
(Date:2/26/2017)... ... 26, 2017 , ... ODH, Inc.™ announced today it will exhibit and ... Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., ... improve Medicaid population health management. , ODH will also have an exhibit booth where ...
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... ... 24, 2017 , ... An in-depth computational analysis of genetic variants implicated in ... eight genes that may explain why susceptibility to one of the disorders could place ... published today in the journal npj Schizophrenia. , “There is a wealth of ...
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans and ... that we all are aware of our options and are empowered with strength ... the launch of its newest edition of "Vision and Hearing" in USA Today, ...
Breaking Medicine News(10 mins):